Eric Creizman Examines Ketamine's Regulatory Challenges in Pharmaceutical Executive

Partner Eric Creizman recently published an article in Pharmaceutical Executive titled “Ketamine's Regulatory Reckoning: From Rapid Growth to Enforcement,” analyzing how the rapid expansion of ketamine therapy—particularly through telemedicine and investor-backed clinic models—has outpaced the development of clear regulatory standards.

In the absence of comprehensive regulatory standards, oversight is increasingly being defined through audits, investigations, and enforcement actions, state medical boards, and, in some cases, prosecutors. The article examines how regulators evaluate ketamine providers across delivery models, the operational practices that tend to draw scrutiny, and the compliance risks emerging as pandemic-era telemedicine flexibilities expire.

As Eric notes, “In the coming years, the defining distinction between sustainable ketamine practices and enforcement targets will not be technology, branding, or scale, but whether independent medical judgment governs how care is delivered.”

Read the full article here.